subject: Womens Infertility - Pipeline Assessment And Market Forecasts To 2017 [print this page] Aarkstore announce a new report "Womens Infertility - Pipeline Assessment and Market Forecasts to 2017 " through its vast collection of market research report.
Summary
The industry analysis specialist, has released its new report, Women's Infertility - Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global womens infertility therapeutics market. The report identifies the key trends shaping and driving the global womens infertility therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global womens infertility sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.
Estimates that the global womens infertility market was valued at $1,417m in 2009 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% to reach $1,609m by 2017. The slow market growth is attributed to the patent expiry of the branded products such as Cetrotide and Ovidrel in 2015. Some key branded products, such as Cetrotide, GONAL-f, Crinone, Ovidrel, Luveris, Pergoveris and Puregon, are going to face a severe threat from generics as they approach patent expiry between 2010 and 2015
Scope
The scope of the report includes:
- Annualized global womens infertility therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017.
- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include Gonadotropin-Releasing hormone (GnRH) antagonists, AMP-activated protein kinase (AMPK) agonists, GnRH agonists, Recombinant human chorionic gonatropin, Follicle stimulating hormone, Selective Estrogen Receptor Modulators (SERMs) and aromatase inhibitor.
- Analysis of the current and future market competition in the global womens infertility therapeutics market. The key future market players covered are Ferring Pharmaceuticals, Dong-A Pharmaceutical Co., Ltd. and PregLem SA and Merck.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the womens infertility market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global womens infertility therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global womens infertility therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
- Whats the next big thing in the global womens infertility therapeutics market landscape? Identify, understand and capitalize.
